EBITDA at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Supernus Pharmaceuticals's EBITDA?
- Supernus Pharmaceuticals (SUPN) reported EBITDA of $17.8M in Q1 2026.
- How has Supernus Pharmaceuticals's EBITDA changed year-over-year?
- Supernus Pharmaceuticals's EBITDA increased by 75.8% year-over-year, from $10.13M to $17.8M.
- What is the long-term trend for Supernus Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's EBITDA has grown at a -29.5% compound annual growth rate (CAGR), from $118.62M to $29.28M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.